Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Eur J Cancer
; 137: 272-284, 2020 09.
Article
in En
| MEDLINE
| ID: mdl-32827847
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Stomach Neoplasms
/
Esophageal Neoplasms
/
Adenocarcinoma
/
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Non-Small-Cell Lung
/
Carcinoma, Hepatocellular
/
Antibodies, Monoclonal, Humanized
/
Liver Neoplasms
/
Antibodies, Monoclonal
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Eur J Cancer
Year:
2020
Type:
Article